[go: up one dir, main page]

AR064397A1 - Derivados de heteroaril-pirrolidinil -y- piperidinil-cetona - Google Patents

Derivados de heteroaril-pirrolidinil -y- piperidinil-cetona

Info

Publication number
AR064397A1
AR064397A1 ARP070105673A ARP070105673A AR064397A1 AR 064397 A1 AR064397 A1 AR 064397A1 AR P070105673 A ARP070105673 A AR P070105673A AR P070105673 A ARP070105673 A AR P070105673A AR 064397 A1 AR064397 A1 AR 064397A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
alkoxy
heteroaryl
aryl
Prior art date
Application number
ARP070105673A
Other languages
English (en)
Inventor
Stephen M Lynch
Ann Marie Madera
Matthew C Lucas
Pravin Iyer
Clara Jeou Jen Lin
Kerem Erol Ozboya
Robert James Welkert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39262542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR064397(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR064397A1 publication Critical patent/AR064397A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Seasonings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se proporcionan composiciones farmacéuticas, métodos de uso y métodos de obtencion de los compuestos. Reivindicacion 1: Un compuesto de la formula 1, o una sal farmacéuticamente aceptables del mismo, en la que: m es un numero de 0 a 3; n es un numero de 0 a 2; Ar es: indolilo opcionalmente sustituido; indazolilo opcionalmente sustituido; azaindolilo opcionalmente sustituido; azaindazolilo opcionalmente sustituido; 2,3-dihidro-indolilo opcionalmente sustituido; 1,3-dihidro-indol-2-on-ilo opcionalmente sustituido; benzotiofenilo opcionalmente sustituido; bencimidazolilo opcionalmente sustituido; benzoxazolilo opcionalmente sustituido; bencisoxazolilo opcionalmente sustituido; benzotiazolilo opcionalmente sustituido; bencisotiazolilo opcionalmente sustituido; quinolinilo opcionalmente sustituido; 1,2,3,4-tetrahidroquinolinilo opcionalmente sustituido; quinolin-2-on-ilo opcionalmente sustituido; isoquinolinilo opcionalmente sustituido; naftalenilo opcionalmente sustituido; piridinilo opcionalmente sustituido; tiofenilo opcionalmente sustituido; pirrolilo opcionalmente sustituido; o fenilo opcionalmente sustituido; R1 es: alquilo C1-6, alquenilo C2-6, alquinilo C2-6, hetero-alquilo C1-6, halo-alquilo C1-6, halo- alquenilo C2-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-6, alquil C1-6-cicloalquil C3-6-alquilo C1-6, alcoxi C1-6, alquilsulfonilo C1-6, alquilsulfanilo C1-6, arilo opcionalmente sustituido; heteroarilo opcionalmente sustituido; heterociclil- alquilo C1-6, aril-alquilo C1-3, cuya porcion arilo está opcionalmente sustituida; heteroaril-alquilo C1-3, cuya porcion heteroarilo está opcionalmente sustituida; ariloxi; aril-alcoxi C1-6, heteroariloxi; o heteroaril-alcoxi C1-6; R2 es hidrogeno; o alquilo C1-6, y Ra y Rb con independencia entre sí son hidrogeno; alquilo C1-6, alcoxi C1-6, halogeno; hidroxi; o oxo; o Ra y Rb forman, juntos, un alquileno C1-2 con la condicion de que cuando m es 1, n es 2 y Ar es fenilo opcionalmente sustituido, entonces R1 no sea metilo ni etilo.
ARP070105673A 2006-12-19 2007-12-18 Derivados de heteroaril-pirrolidinil -y- piperidinil-cetona AR064397A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87596906P 2006-12-19 2006-12-19
US99956107P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
AR064397A1 true AR064397A1 (es) 2009-04-01

Family

ID=39262542

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105673A AR064397A1 (es) 2006-12-19 2007-12-18 Derivados de heteroaril-pirrolidinil -y- piperidinil-cetona

Country Status (30)

Country Link
US (2) US8084623B2 (es)
EP (3) EP2102157B1 (es)
JP (1) JP5394252B2 (es)
KR (1) KR101054189B1 (es)
CN (1) CN101563319B (es)
AR (1) AR064397A1 (es)
AT (1) ATE513808T1 (es)
BR (1) BRPI0720742B8 (es)
CA (1) CA2671378C (es)
CL (1) CL2007003672A1 (es)
CO (1) CO6190531A2 (es)
CR (1) CR10809A (es)
CY (1) CY1113916T1 (es)
DK (1) DK2354124T3 (es)
EC (1) ECSP099442A (es)
ES (2) ES2366980T3 (es)
HR (1) HRP20130362T1 (es)
IL (1) IL198879A0 (es)
MA (1) MA31142B1 (es)
MX (1) MX2009006334A (es)
MY (1) MY186650A (es)
NO (1) NO20092058L (es)
NZ (1) NZ577114A (es)
PE (2) PE20081831A1 (es)
PL (1) PL2354124T3 (es)
PT (1) PT2354124E (es)
RU (1) RU2479575C2 (es)
SG (1) SG170054A1 (es)
TW (1) TWI377202B (es)
WO (1) WO2008074703A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515355A (ja) * 2008-03-20 2011-05-19 エフ.ホフマン−ラ ロシュ アーゲー ピロリジニル誘導体およびその使用
JP2011524396A (ja) 2008-06-18 2011-09-01 エフ.ホフマン−ラ ロシュ アーゲー Mriとしてのアリールケトン
JP5749181B2 (ja) * 2009-02-09 2015-07-15 スノビオン プハルマセウトイカルス インコーポレイテッド ピロリジントリプル再取込み阻害剤
JP5992192B2 (ja) * 2012-03-30 2016-09-14 三井金属鉱業株式会社 パラジウム触媒
WO2013160273A1 (en) 2012-04-25 2013-10-31 F. Hoffmann-La Roche Ag (3,4-dichloro-phenyl)-((s)-3-propyl-pyrrolidin-3-yl)-methanone hydrochloride and manufacturing processes
EP2961746B1 (en) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
CN110642880B (zh) * 2019-10-11 2021-12-31 长沙麓兴生物科技有限公司 一种氮未取代吡唑和吲唑类硼酸的制备方法
CN114014792B (zh) * 2021-12-15 2024-01-26 沈阳海诺威医药科技有限公司 一种7-(4-溴苯甲酰基)-1,3-二氢-2h-吲哚-2-酮的制备方法
CA3244552A1 (en) 2022-02-28 2023-08-31 Noema Pharma Ag TRIPLE ABSORBENT INHIBITOR FOR THE TREATMENT OF ATYPICAL DEPRESSION
CN116751157B (zh) * 2023-06-21 2025-09-12 上海再启生物技术有限公司 一种2-(2-氨基-5-溴-苯甲酰基)吡啶的放大制备方法
TW202525282A (zh) 2023-08-28 2025-07-01 瑞士商諾埃瑪製藥公司 使用三重再攝取抑制劑治療行為免疫-代謝叢集病症或疾病之方法
WO2025046050A1 (en) * 2023-08-30 2025-03-06 Noema Pharma Ag Methods of treating a sleep disorder using a triple reuptake inhibitor
WO2025106383A1 (en) * 2023-11-17 2025-05-22 Merck Sharp & Dohme Llc Pyrrolidinyl derivatives useful as hcn1/hcn 2 modulators
TW202535357A (zh) * 2024-01-05 2025-09-16 瑞士商諾埃瑪製藥公司 治療更年期及近更年期之方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3073829A (en) * 1963-01-15 Certificate of correction
US2248018A (en) * 1939-03-30 1941-07-01 Winthrop Chem Co Inc 4-aryl-piperidine-ketones and a process of preparing them
US3056795A (en) * 1958-04-30 1962-10-02 Sterling Drug Inc 3-aryl-3-(aroyl or alkanoyl)tropanes and preparation thereof
NL262366A (es) 1960-03-14
US4341698A (en) * 1979-06-21 1982-07-27 Richardson-Merrell Inc. Enkaphalin derivatives
GB2060937A (en) 1979-10-12 1981-05-07 Rolls Royce Fluid-flow restrictor assembly
ZA806501B (en) 1979-10-27 1981-10-28 Richardson Merrell Inc 4-(4-alkyl-aroyl-1-piperidino)butyrophenone antipsychotic agents
US4443451A (en) * 1981-07-15 1984-04-17 Janssen Pharmaceutica N.V. Bicyclic pyrimidin-5-one derivatives
CA1228867A (en) 1984-05-03 1987-11-03 G. Paull Torrence Methanol carbonylation process
EP0507863A4 (en) 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
FR2735127B1 (fr) 1995-06-09 1997-08-22 Pf Medicament Nouvelles piperazines heteroaromatiques utiles comme medicaments.
GB9523583D0 (en) * 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
FR2758327B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles arylpiperazines derivees de piperidine
US6281243B1 (en) * 1998-02-26 2001-08-28 Akzo Nobel N.V. Derivatives of azetidine and pyrrolidine
WO2001014331A2 (en) 1999-08-24 2001-03-01 Regents Of The University Of California Non-quinoline inhibitors of malaria parasites
US20020151712A1 (en) * 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
AU7315700A (en) * 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist
CA2389049A1 (en) * 1999-09-27 2001-04-05 Georgetown University Dopamine transporter inhibitors and their use
AU9087301A (en) 2000-09-11 2002-03-26 Sepracor Inc Ligands for monoamine receptors and transporters, and methods of use thereof
US6803362B2 (en) 2001-03-09 2004-10-12 Ortho-Mcneil Pharmaceutical Inc. Heterocyclic compounds
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US20040034019A1 (en) 2002-08-08 2004-02-19 Ronald Tomlinson Piperazine and piperidine derivatives
WO2004022712A2 (en) 2002-09-03 2004-03-18 Scios Inc. INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE
AU2003268493A1 (en) * 2002-09-11 2004-04-30 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists
JP2006506451A (ja) 2002-10-11 2006-02-23 アストラゼネカ アクチボラグ 1,4−ジ置換ピペリジン誘導体および11−βHSD1阻害薬としてのそれらの使用
WO2004080925A2 (en) 2003-03-12 2004-09-23 The University Of Western Ontario Synthesis of tetrahydro-1,2-oxazines by the cycloaddition of nitrones with cyclopropanes
US20060014987A1 (en) 2003-07-07 2006-01-19 Lan Huang Synthesis of beta-elemene, intermediates thereto, analogues and uses thereof
JP2005057154A (ja) * 2003-08-07 2005-03-03 Canon Inc 露光装置
AU2004283842A1 (en) 2003-10-24 2005-05-06 F. Hoffmann-La Roche Ag CCR3 receptor antagonists
GB0325745D0 (en) 2003-11-05 2003-12-10 Astrazeneca Ab Chemical compounds
KR20050045927A (ko) 2003-11-12 2005-05-17 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제
WO2005082904A1 (ja) 2004-02-26 2005-09-09 Kyowa Hakko Kogyo Co., Ltd. 好中球性炎症疾患の予防及び/または治療剤
NZ551663A (en) 2004-06-21 2009-09-25 Hoffmann La Roche Indole derivatives as histamine receptor antagonists
KR101211950B1 (ko) 2004-06-30 2012-12-13 얀센 파마슈티카 엔.브이. Parp 저해제로서의 프탈아진 유도체
AR051094A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
GT200500375A (es) * 2004-12-20 2006-11-28 Derivados de piperidina y su uso como agentes antiinflamatorios
DE102004061934A1 (de) 2004-12-22 2006-07-13 Siemens Ag Verfahren zur Datenübertragung zwischen einer sendenden und einer empfangenden Einheit in einem Bluetooth-Funkkommunikationssystem
RU2440996C2 (ru) 2005-01-25 2012-01-27 Галенеа Корп. Замещенные ариламины и их применение в качестве модуляторов 5-ht6-рецептора
WO2006086609A2 (en) 2005-02-10 2006-08-17 Axys Pharmaceuticals, Inc. Inhibitors of tryptase
AU2006326134B2 (en) 2005-12-12 2012-07-19 Nerviano Medical Sciences S.R.L. Substituted pyrazolo [4,3-c] pyridine derivatives active as kinase inhibitors
AU2007235578B2 (en) 2006-04-07 2011-07-14 Janssen Pharmaceutica N.V. Indoles and benzoimidazoles as modulators of the histamine H4 receptor

Also Published As

Publication number Publication date
EP2102157B1 (en) 2011-06-22
MX2009006334A (es) 2009-06-23
CO6190531A2 (es) 2010-08-19
US8084623B2 (en) 2011-12-27
ECSP099442A (es) 2009-07-31
CN101563319B (zh) 2012-09-05
HRP20130362T1 (en) 2013-05-31
BRPI0720742B1 (pt) 2021-02-09
ES2401129T3 (es) 2013-04-17
CA2671378C (en) 2015-10-20
ATE513808T1 (de) 2011-07-15
SG170054A1 (en) 2011-04-29
MA31142B1 (fr) 2010-02-01
ES2366980T3 (es) 2011-10-27
EP2684871B1 (en) 2016-05-04
TW200838859A (en) 2008-10-01
PE20081831A1 (es) 2008-12-27
AU2007336375A1 (en) 2008-06-26
KR101054189B1 (ko) 2011-08-03
CN101563319A (zh) 2009-10-21
DK2354124T3 (da) 2013-03-11
US8513425B2 (en) 2013-08-20
EP2354124A2 (en) 2011-08-10
NO20092058L (no) 2009-09-17
WO2008074703A1 (en) 2008-06-26
KR20090091194A (ko) 2009-08-26
US20080146607A1 (en) 2008-06-19
CR10809A (es) 2009-06-25
MY186650A (en) 2021-08-03
TWI377202B (en) 2012-11-21
JP5394252B2 (ja) 2014-01-22
CA2671378A1 (en) 2008-06-26
EP2684871A1 (en) 2014-01-15
BRPI0720742B8 (pt) 2021-05-25
RU2009122666A (ru) 2011-01-27
PT2354124E (pt) 2013-04-09
RU2479575C2 (ru) 2013-04-20
PE20121151A1 (es) 2012-08-27
CL2007003672A1 (es) 2008-07-25
US20120065225A1 (en) 2012-03-15
NZ577114A (en) 2011-12-22
EP2102157A1 (en) 2009-09-23
CY1113916T1 (el) 2016-07-27
JP2010513379A (ja) 2010-04-30
PL2354124T3 (pl) 2013-07-31
EP2354124B1 (en) 2013-02-13
IL198879A0 (en) 2010-02-17
EP2354124A3 (en) 2011-09-14
BRPI0720742A2 (pt) 2014-01-28

Similar Documents

Publication Publication Date Title
AR064397A1 (es) Derivados de heteroaril-pirrolidinil -y- piperidinil-cetona
ES2525932T3 (es) Derivados de dihidrotetrabenazina radiomarcados y su uso como agentes de imagenología
MA34604B1 (fr) Derives de la pyrazine en tant que bloqueurs de l&#39;enac
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR081649A1 (es) Compuestos heteroarilo nitrogenados
JP2010265321A5 (es)
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
CO5310534A1 (es) Nuevos derivados de androstano anti-inflamatorios
AR064279A1 (es) Compuestos basados en la 4-fenil-6-(2,2,2-trifluoro-1- feniletoxi) pirimidina y metodos de uso de los mismos
CY1114892T1 (el) Φαρμακευτικη συνθεση ενος ισχυρου αναστολεα του hcv για απο του στοματος χορηγηση
AR061134A1 (es) Derivados de tioxantina
AR051288A1 (es) Derivados de pirazol condensado, su preparacion y su aplicacion terapeutica
AR040080A1 (es) Inhibidores del virus de la hepatitis c
ES2640911T3 (es) Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus
PE20090211A1 (es) Inhibidores de las iap
CO6190626A2 (es) Compuestos y composiciones como inhibidores de proteasa activadora de canal
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
ES2173846T3 (es) Compuestos de biciclocarbonil indol como agentes antiinflamatorios/analgesicos y como inhibidores de cox-2.
PE20081315A1 (es) Derivados de benzimidazol como antagonistas de vr-1
MA33836B1 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma
AR055041A1 (es) Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
AR065509A1 (es) Derivados heterociclicos de imidazol, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos inflamatorios y autoinmunes.
AR073565A1 (es) Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los contienen
AR077301A1 (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano como antagonistas de 5-ht1a y 5-ht1b

Legal Events

Date Code Title Description
FA Abandonment or withdrawal